MOLECULAR DOCKING OF GANOMESTENOL WITH SARS-COV-2 MPRO
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i2.43679Keywords:
Molecular docking, SARS-CoV-2, Ganomestenol, N3 InhibitorAbstract
Objective: The present study focused on binding mode of the N3 inhibitor and Ganomestenol with receptor SARS-CoV-2 Mpro protease.
Methods: The structure of ligands N3 inhibitor and Ganomestenol were designed and 3-D coordinates were prepared using ACD/ChemSketch 8.0 freeware. Autodock4 software was used to study the orientation of the inhibitor or ligand in the active site of biological receptor SARS-CoV-2 Mpro (PDB ID: 6LU7). The Lamarckian genetic algorithm was applied to both ligand and protein for energy minimization using default parameters. The results were analyzed by Ligplot and Pymol software.
Results: The compound Ganomestenol designed in in-silico for molecular docking with SARS-CoV-2 protease (Mpro). The in-silico results showed significant binding energy (−6.93 kcal/mol) by comparing with N3 inhibitor (−3.51 kcal/mol).
Conclusion: The affinity of Ganomestenol is highly significant compared to N3 inhibitor and also showed efficacy of ligand toward protease under in-silico condition.
Downloads
References
Galante O, Avni YS, Fuchs L, Ferster OA, Almog Y. Coronavirus NL63-induced adult respiratory distress syndrome. Am J Respir Crit Care Med 2016;193:100-1.
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477.
Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol 2017;89:1040-7.
Mulangu S, Dodd LE, Davey RT Jr., Mbaya OT, Proschan M, Mukadi D. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl J Med 2019;381:2293-303.
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Cao B. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet 2020;395:497-6.
Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 2003;100:13190-5.
Kumar KJ, Venkatesh. Antimicrobial Property of Crude Extracts and Bioactive from Macro Fungi of Ganoderma Species. Vol. 1. Bengaluru: InSc Publisher; 2020. p. 31-9.
Zhang W, Tao J, Yang X, Yang Z, Zhang L, Liu H, et al. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem Biophys Res Commun 2014;449:307-12.
Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, et al. Design of wide-spectrum inhibitors targeting Coronavirus main proteases. PLoS Biol 2005;3:e324.
Liu X, Wang XJ. Potential inhibitors against 2019-nCoV Coronavirus M protease from clinically approved medicines. J Genet Genomics 2020;47:119-21.
Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980;36:3219-28.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020;582:289-93.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.
Laskowski RA, Swindells MB. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011;51:2778-86.
Chang KO, Kim Y, Lovell S, Rathnayake AD, Groutas WC. Antiviral drug discovery: Norovirus proteases and development of inhibitors. Viruses 2019;11:197.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Venkatesh
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
